Daniel Gallo, Ph.D.

Dr. Gallo was appointed senior vice president of medical affairs and advocacy of Zevra Therapeutics (then KemPharm, Inc.) in January 2023.

Prior to Zevra, Dr. Gallo established Jaguar Gene Therapy LLC’s medical affairs organization and was instrumental in advancing its clinical and regulatory strategies through external collaborations and partnerships with advocacy.

Prior to that, Dr. Gallo was vice president and head of U.S. medical affairs at Orphazyme, the company which developed arimoclomol and whose assets KemPharm acquired in 2022. Among his accomplishments at Orphazyme, Dr. Gallo was responsible for establishing a 15-site U.S. expanded access program (EAP) that continues to support NPC patients across the country. Additionally, he built Orphazyme’s field medical team and led planning and execution of external engagement and collaboration, evidence generation, and scientific communications.

Dr. Gallo’s career is also highlighted by launch experience and medical strategy roles with global pharmaceutical companies, including Sanofi Genzyme, Johnson & Johnson, AbbVie, and Shire.

Dr. Gallo earned his doctorate in cell and molecular biology at Northwestern University.